Evidence map›Paper›PMID 36256497›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Hijacking the Peptidoglycan Recycling Pathway of Escherichia coli to Produce Muropeptides.

Antoine Rousseau, Julie Michaud, Stéphanie Pradeau, Sylvie Armand, Sylvain Cottaz, Emeline Richard, Sébastien Fort

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antoine RousseauUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Julie MichaudUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Stéphanie PradeauUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Sylvie ArmandUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Sylvain CottazUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Emeline RichardUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.
Sébastien FortUniv. Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France.ORCID http://orcid.org/0000-0002-6133-9900

Funding

Agence Nationale de la Recherche ANR-20-CE07-0012-01
6 · The paper itself

Abstract

Soluble fragments of peptidoglycan called muropeptides are released from the cell wall of bacteria as part of their metabolism or as a result of biological stresses. These compounds trigger immune responses in mammals and plants. In bacteria, they play a major role in the induction of antibiotic resistance. The development of efficient methods to produce muropeptides is, therefore, desirable both to address their mechanism of action and to design new antibacterial and immunostimulant agents. Herein, we engineered the peptidoglycan recycling pathway of Escherichia coli to produce N-acetyl-β-D-glucosaminyl-(1→4)-1,6-anhydro-N-acetyl-β-D-muramic acid (GlcNAc-anhMurNAc), a common precursor of Gram-negative and Gram-positive muropeptides. Inactivation of the hexosaminidase nagZ gene allowed the efficient production of this key disaccharide, providing access to Gram-positive muropeptides through subsequent chemical peptide conjugation. E. coli strains deficient in both NagZ hexosaminidase and amidase activities further enabled the in vivo production of Gram-negative muropeptides containing meso-diaminopimelic acid, a rarely available amino acid.

Indexed as

Escherichia coliPeptidoglycanBacteriaCell WallHexosaminidasesHexosaminidasesPeptidoglycandiaminopimelic acid, Escherichia colimetabolic engineeringmuropeptidespeptidoglycan

Identifiers

PMID36256497
PMCPMC10107939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.